Codexis (CDXS) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenues: $15.2 million for Q1 2026, up from $7.5 million in Q1 2025, primarily due to revenue recognition from a Merck technology transfer agreement.

Product Gross Margin: 71% in Q1 2026, compared to 55% in Q1 2025, driven by a favorable product mix.

R&D Expenses: $11.4 million, down from $12.9 million in the prior year, reflecting lower allocable costs despite increased employee-related expenses.

SG&A Expenses: $9.8 million, down from $12.4 million, due to reduced headcount and lower stock-based compensation.

Net Loss: $8.7 million, improved from a loss of $20.7 million in Q1 2025.

Cash Position: $65.1 million at the end of Q1 2026, down from $78.2 million at the end of 2025, expected to fund operations through the end of 2027.

2Strategic Updates and Business Highlights

Codexis is advancing its ECO Synthesis platform for RNA medicine production, addressing scalability and environmental impact in manufacturing.

The company is preparing to present new data on its ECO Synthesis technology at the upcoming TIDES Conference, emphasizing advancements in stereochemical control of siRNA.

The small molecule biocatalysis business remains stable, supporting 13 commercial products, including a recently approved HIV treatment in partnership with Merck.

There are over 50 opportunities in the sales pipeline, with strong interest from 40 companies, indicating a robust demand for enzymatic production solutions.

3Forward Guidance and Outlook

Codexis maintains its revenue guidance for 2026, expecting total revenue between $72 million and $76 million, with a heavier weighting towards the second half of the year.

The company is on track to achieve a half-kilogram scale for its ECO Synthesis platform by the end of 2026, with plans for a new GMP facility to be operational by the end of 2027.

4Bad News, Challenges, or Points of Concern

The decline in cash reserves from the previous quarter raises concerns about funding for ongoing projects and capital expenditures.

The transition from small-scale to larger-scale production poses inherent risks, including process control challenges and the need for extensive validation as production scales up.

The competitive landscape in RNA medicine manufacturing is intensifying, with increasing demand potentially outpacing current production capabilities.

5Notable Q&A Insights

Management highlighted the upcoming TIDES presentation, which will showcase new data on stereochemical control, a significant differentiator for their siRNA products.

There are ongoing discussions with the FDA regarding the ECO Synthesis platform, with potential for faster approval timelines if the Advanced Manufacturing Technologies designation is achieved.

The company is optimistic about securing new strategic partnerships by the end of 2026, with positive engagement from existing CDMO partnerships.

The sales funnel includes a diverse mix of large pharma, biotech, and emerging biotech companies, indicating a broad interest in their technology across various market segments. Overall, Codexis is positioned for growth in the RNA medicine space, with a strong focus on innovation and strategic partnerships, despite facing challenges related to scaling production and cash management.